What Is the NMPA Acceptance Threshold for Foreign Drug Applications?

For foreign pharmaceutical companies considering entry into the Chinese market, understanding the NMPA’s acceptance threshold for drug registration applications is a fundamental strategic question. The acceptance threshold — the minimum quality standard that an application must meet to be formally accepted for review — has undergone significant evolution since the 2019 Drug Administration Law, with the NMPA shifting from a document-focused acceptance check to a more substantive pre-review process that evaluates both completeness and basic quality. This article provides a comprehensive examination of the acceptance thresholds that foreign drug applications must meet.

The Two-Stage Acceptance Process

The NMPA’s acceptance of a foreign drug registration application occurs in two distinct stages:

Stage 1: Formal Acceptance Review (Shou Li)

Upon submission, the NMPA’s administrative acceptance office conducts a formal review to determine whether the application dossier is complete and meets basic submission requirements. This review focuses on:

• Application form completeness: All required fields completed, correct fee category selected, appropriate application type designated
• Supporting document availability: All required certificates, letters of authorization, and supporting documents included
• Legal entity verification: Proof of the applicant’s legal status and authorization to submit the application in China
• Fee payment: Confirmation that the application fee has been paid
• Chinese language compliance: All required documents in Chinese language
• Electronic submission format: Documents submitted through the correct CDE portal in the required format

The formal acceptance review is typically completed within 5 to 10 working days. If deficiencies are identified, the NMPA issues a notice of supplementary requirements (Bu Zheng Tong Zhi), allowing the applicant 30 days to correct the deficiencies. If deficiencies are not corrected within the specified timeframe, the application is rejected.

Stage 2: Technical Pre-Review (Ji Shu Yu Shen)

Once the formal acceptance is confirmed, the application enters a technical pre-review phase conducted by the CDE. This phase, introduced under the 2020 Drug Registration Regulation, represents a significant shift in the NMPA’s approach to acceptance thresholds. Rather than simply accepting all formally complete applications for full review, the CDE now conducts an initial technical assessment to determine whether the application has a reasonable likelihood of meeting the NMPA’s substantive requirements.

The technical pre-review evaluates:

• Scientific validity: Whether the drug’s mechanism of action is well-founded and supported by adequate preclinical data
• Clinical data quality: Whether the submitted clinical data is from well-designed trials with appropriate endpoints and statistical methods
• CMC data sufficiency: Whether the chemistry, manufacturing, and controls data package provides adequate assurance of drug quality and consistency
• Benefit-risk assessment: A preliminary assessment of whether the drug’s benefits are likely to outweigh its risks for the claimed indication
• Regulatory completeness: Whether the application addresses all questions and concerns raised during pre-submission consultations with the CDE

Applications that pass the technical pre-review are formally accepted for full review. Applications that fail the pre-review may be rejected without a full evaluation, particularly if the deficiencies are fundamental to the application’s scientific basis.

Minimum Requirements by Application Type

New Drug Applications (NDA) for Innovative Drugs

For foreign innovative drugs (Class 1 in the NMPA’s classification system), the acceptance threshold requires:

• Complete non-clinical data package: Including pharmacology, pharmacokinetics, and toxicology studies conducted in accordance with Good Laboratory Practice (GLP) standards. The non-clinical package must be sufficient to support the proposed clinical trials and provide a reasonable safety assessment for the intended patient population.
• Clinical data from at least one adequate and well-controlled trial: For drugs already approved in foreign markets, the clinical data should demonstrate substantial evidence of efficacy and an acceptable safety profile. For drugs seeking first global approval in China, the clinical data requirements are more stringent.
• Complete CMC data: Including drug substance and drug product specifications, manufacturing process validation, stability data under at least 12 months of accelerated and long-term conditions, and impurity characterization.
• GMP compliance certification: Evidence of current GMP compliance for the manufacturing site, either through NMPA inspection or accepted foreign GMP certificate.
• Labeling and prescribing information: Draft Chinese-language labeling, patient information leaflet, and prescribing information that conforms to NMPA format and content requirements.

Abbreviated New Drug Applications (ANDA) for Generics

For foreign generic drug applications (Class 3 and Class 4), the acceptance threshold includes:

• Bioequivalence (BE) data: A BE study comparing the generic product to the reference listed drug (RLD) in the Chinese population, or a BE study demonstrating comparability with a bridging strategy to foreign BE data. The BE study must be conducted at an NMPA-qualified clinical trial site.
• Quality by Design (QbD) data: Evidence that the generic product’s quality attributes have been systematically designed and controlled to match the RLD.
• Complete impurity profile comparison: Impurities must not exceed those in the RLD or identified ChP limits.
• Dissolution profile comparability: Dissolution testing under multiple pH conditions demonstrating similarity to the RLD.
• Reference product sourcing documentation: Evidence that the RLD used for BE studies is the Chinese-marketed reference product or an acceptable alternative.

Biological Product Applications

For foreign biological products, including biosimilars, the acceptance threshold is the most stringent:

• Extensive analytical similarity data: Comprehensive structural and functional characterization demonstrating similarity to the reference biological product.
• Non-clinical comparability data: Including in vitro functional assays, animal PK/PD studies, and toxicology assessments.
• Clinical comparability data: At least one clinical study (pharmacokinetic comparability for most products, with at least one clinical efficacy/safety study for complex products).
• Immunogenicity data: Comprehensive immunogenicity assessment including anti-drug antibody incidence, titers, and neutralizing antibody data.
• Viral safety data: Complete viral clearance validation studies for cell-derived products.
• Stability data under Chinese conditions: Including Zone IVa climatic conditions (30°C/65% RH for long-term studies).

Common Reasons for Application Rejection at the Acceptance Stage

The NMPA publishes statistics on application acceptance outcomes, and analysis of rejection patterns reveals the following common deficiencies:

1. Inadequate clinical data: The most common reason for rejection at the technical pre-review stage. Applications submitted without adequate Phase 3 data or with data from trials that do not meet CDE standards for trial design, endpoint selection, or statistical analysis are frequently rejected.
2. Missing Chinese Pharmacopoeia compliance: APIs and finished products that do not meet ChP specifications for impurities, dissolution, or identification testing are rejected at the pre-review stage.
3. Incomplete CMC data: Missing stability data (particularly under Chinese climatic conditions), incomplete process validation, or inadequate impurity characterization.
4. Ethnic sensitivity concerns: Applications that do not adequately address the potential for ethnic differences in drug response, particularly for drugs metabolized through pathways with known Asian genetic polymorphisms.
5. GMP compliance gaps: Foreign manufacturers without current GMP certification accepted by the NMPA face rejection at the acceptance stage.
6. Translation quality issues: Poor-quality Chinese translations that create ambiguity about critical scientific or regulatory information can lead to acceptance refusal.

Strategies for Meeting the Acceptance Threshold

Pre-Submission Consultation: The Most Important Step

The single most effective strategy for ensuring acceptance is to engage in the CDE’s formal pre-submission consultation process. The CDE offers several consultation mechanisms:

• Type A consultation: For critical development issues, with a response within 30 working days
• Type B consultation: For general drug development questions, with a response within 60 working days
• Type C consultation: For other regulatory matters, with a response within 90 working days

A well-prepared pre-submission consultation package that presents the key data and addresses CDE expectations can identify potential acceptance issues before the formal application is submitted, allowing the sponsor to address them proactively.

Comprehensive Data Gap Analysis

Foreign companies should conduct a structured comparison of their existing data packages against NMPA-specific requirements before initiating the application process. Key gaps to identify include:

• Missing or incomplete stability data under ChP-specified conditions
• Analytical method differences between manufacturer’s methods and ChP methods
• Ethnic sensitivity data requirements (PK bridging studies, pharmacogenomic analysis)
• Specific Chinese population clinical data needs
• Labeling and prescribing information format requirements

Quality Translation and Localization

The acceptance threshold includes a practical assessment of whether the Chinese-language application is comprehensible and scientifically accurate. Foreign companies should invest in professional translation by translators with pharmaceutical regulatory expertise, followed by review by a Chinese regulatory affairs professional who can verify both the linguistic accuracy and the regulatory appropriateness of the translation.

Conclusion

The NMPA’s acceptance threshold for foreign drug applications has evolved from a simple document completeness check to a meaningful two-stage process that evaluates both formal compliance and basic scientific merit. Foreign companies that invest in pre-submission consultation, comprehensive data gap analysis, high-quality translation, and thorough preparation of technical documentation will significantly increase their chances of passing both the formal acceptance review and the technical pre-review. As the NMPA continues to align its regulatory framework with international standards while maintaining its own specific quality expectations, understanding and meeting the acceptance threshold remains a critical first step in the drug registration journey for any foreign pharmaceutical company seeking access to the Chinese market.

Disclaimer: This article provides general guidance and does not constitute legal or regulatory advice. Foreign pharmaceutical companies should consult with qualified regulatory affairs professionals and legal counsel for their specific registration strategies in China.